28888

544319

SENORES

img img img img
No Data Available

Experience smart and hassle-free investing in minutes with Bajaj Broking! *T&C apply

SENORES PHARMACEUTICALS L Share Price Today

SENORES PHARMACEUTICALS L is currently trading at ₹1283.2, down by ₹6.8 from the previous close. The stock touched an intraday high of ₹1311.00 and a low of ₹1252.90 during the latest trading session. Over the past one year, SENORES PHARMACEUTICALS L has delivered a return of 136.19%, while the stock has gained 38.27% in the last one month.

SENORES PHARMACEUTICALS L performance

Today’s low Today’s high
₹ 1252.90 ₹ 1311.00
₹ 1283.20
52 week low 52 week high
₹ 513.00 ₹ 1311.00
₹ 1283.20
Open Price ₹ 1299.10
Prev. Close ₹ 1290.00
Volume (Shares) 557292.00
Total traded value ₹ 7151.17
Upper Circuit ₹ 1548.00
Lower Circuit ₹ 1032.00
info

Investment Returns

Over 1 Month 38.27% Over 3 Months 75.14% Over 6 Months 64.10% Over 1 Year 136.19%
demotext Smart Investing Starts here ! Trade Smart with Fast Execution & Zero Account Opening Fees Invest Now

SENORES PHARMACEUTICALS L fundamentals


  • Market cap (Cr) 5,909.60
  • P/E Ratio (TTM) 293.47
  • Beta 1.12
  • Book Value / share 162.83
  • Return on equity 0.84%
  • EPS (TTM) 4.40
  • Dividend yield 0.00%
  • Net profit/quarter (Cr) 8.48
info icon alternate text
  • Market cap (Cr) 5,824.90
  • P/E Ratio (TTM) 293.47
  • Beta 0.97
  • Book Value / share 162.83
  • Return on equity 0.84%
  • EPS (TTM) 4.40
  • Dividend yield 0.00%
  • Net profit/quarter (Cr) 8.48
info icon alternate text

SENORES PHARMACEUTICALS L Financials

  • Key Results
  • Key Ratios
  • Balance sheet
  • Cash Flow
  • Competition
info-icon
Revenue
Net income
Particulars MAR 2026 (Values in Cr)
Revenue 36.81
Operating Expense 46.31
Net Profit 8.48
Net Profit Margin (%) 23.03
Earnings Per Share (EPS) 1.84
EBITDA 18.71
Effective Tax Rate (%) 33.17
Particulars DEC 2025 (Values in Cr)
Revenue 25.15
Operating Expense 35.02
Net Profit 2.65
Net Profit Margin (%) 10.53
Earnings Per Share (EPS) 1.98
EBITDA 8.84
Effective Tax Rate (%) 24.50
Particulars SEP 2025 (Values in Cr)
Revenue 20.92
Operating Expense 39.04
Net Profit 6.43
Net Profit Margin (%) 30.73
Earnings Per Share (EPS) 1.40
EBITDA 12.88
Effective Tax Rate (%) 15.94
Particulars JUN 2025 (Values in Cr)
Revenue 15.49
Operating Expense 24.62
Net Profit 2.70
Net Profit Margin (%) 17.43
Earnings Per Share (EPS) 0.59
EBITDA 7.22
Effective Tax Rate (%) 24.79
Particulars MAR 2025 (Values in Cr)
Revenue 11.86
Operating Expense 18.22
Net Profit 2.01
Net Profit Margin (%) 16.94
Earnings Per Share (EPS) 0.39
EBITDA 6.51
Effective Tax Rate (%) 30.44
Particulars MAR 2026 (Values in Cr)
Revenue 106.09
Operating Expense 144.98
Net Profit 20.25
Net Profit Margin (%) 19.08
Earnings Per Share (EPS) 4.40
EBITDA 47.67
Effective Tax Rate (%) 26.25
Particulars MAR 2025 (Values in Cr)
Revenue 38.54
Operating Expense 55.42
Net Profit 3.69
Net Profit Margin (%) 9.57
Earnings Per Share (EPS) 1.02
EBITDA 14.70
Effective Tax Rate (%) 27.78
Particulars MAR 2024 (Values in Cr)
Revenue 34.01
Operating Expense 38.83
Net Profit 0.81
Net Profit Margin (%) 2.38
Earnings Per Share (EPS) 0.35
EBITDA 6.78
Effective Tax Rate (%) 60.09
Particulars MAR 2023 (Values in Cr)
Revenue 12.38
Operating Expense 17.23
Net Profit 1.20
Net Profit Margin (%) 9.69
Earnings Per Share (EPS) 1.26
EBITDA 5.01
Effective Tax Rate (%) 38.14
Particulars MAR 2022 (Values in Cr)
Revenue 15.85
Operating Expense 15.98
Net Profit 0.29
Net Profit Margin (%) 1.82
Earnings Per Share (EPS) 0.33
EBITDA 1.97
Effective Tax Rate (%) 67.77
Particulars MAR 2025 (Values in Cr)
Book Value / Share 170.72
ROE % 11.78
ROCE % 11.75
Total Debt to Total Equity 0.58
EBITDA Margin 27.36
Particulars MAR 2024 (Values in Cr)
Book Value / Share 66.95
ROE % 26.19
ROCE % 12.04
Total Debt to Total Equity 1.28
EBITDA Margin 20.70
Particulars MAR 2023 (Values in Cr)
Book Value / Share 46.36
ROE % 20.54
ROCE % 18.24
Total Debt to Total Equity 0.94
EBITDA Margin 46.29
Particulars MAR 2022 (Values in Cr)
Book Value / Share 41.86
ROE % 2.71
ROCE % 3.33
Total Debt to Total Equity 0.40
EBITDA Margin 17.08
Particulars MAR 2025 (Values in Cr)
Book Value / Share 153.74
ROE % 0.84
ROCE % 2.15
Total Debt to Total Equity 0.23
EBITDA Margin 38.17
Particulars MAR 2024 (Values in Cr)
Book Value / Share 55.10
ROE % 0.78
ROCE % 2.56
Total Debt to Total Equity 0.78
EBITDA Margin 19.94
Particulars MAR 2023 (Values in Cr)
Book Value / Share 39.66
ROE % 3.30
ROCE % 5.44
Total Debt to Total Equity 1.04
EBITDA Margin 40.47
Particulars MAR 2022 (Values in Cr)
Book Value / Share 38.54
ROE % 3.15
ROCE % 4.51
Total Debt to Total Equity 0.43
EBITDA Margin 15.51
Particulars MAR 2021 (Values in Cr)
Book Value / Share 24.91
ROE % 8.87
ROCE % 4.55
Total Debt to Total Equity 0.39
EBITDA Margin 14.79
Particulars MAR 2025 (Values in Cr)
Cash & Short Term Investments 385.50
Total Assets 1226.86
Total Liabilities 1226.86
Total Equity 812.24
Share Outstanding 4
Price to Book Ratio 3.73
Return on Assets (%) 4.77
Return on Capital (%) 5.24
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 13.06
Total Assets 621.88
Total Liabilities 621.88
Total Equity 231.71
Share Outstanding 3
Price to Book Ratio 0.00
Return on Assets (%) 5.05
Return on Capital (%) 6.55
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 0.10
Total Assets 131.05
Total Liabilities 131.05
Total Equity 45.49
Share Outstanding 0
Price to Book Ratio 0.00
Return on Assets (%) 6.43
Return on Capital (%) 7.94
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 3.21
Total Assets 59.15
Total Liabilities 59.15
Total Equity 36.59
Share Outstanding 0
Price to Book Ratio 0.00
Return on Assets (%) 1.67
Return on Capital (%) 1.95
Particulars MAR 2025 (Values in Cr)
Cash & Short Term Investments 359.72
Total Assets 834.09
Total Liabilities 834.09
Total Equity 707.97
Share Outstanding 4
Price to Book Ratio 3.73
Return on Assets (%) 0.44
Return on Capital (%) 0.46
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 10.45
Total Assets 285.86
Total Liabilities 285.86
Total Equity 168.12
Share Outstanding 3
Price to Book Ratio 0.00
Return on Assets (%) 0.28
Return on Capital (%) 0.31
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 0.09
Total Assets 111.71
Total Liabilities 111.71
Total Equity 38.92
Share Outstanding 0
Price to Book Ratio 0.00
Return on Assets (%) 1.07
Return on Capital (%) 1.21
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 1.40
Total Assets 55.16
Total Liabilities 55.16
Total Equity 33.69
Share Outstanding 0
Price to Book Ratio 0.00
Return on Assets (%) 1.23
Return on Capital (%) 1.42
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 1.64
Total Assets 14.95
Total Liabilities 14.95
Total Equity 9.46
Share Outstanding 0
Price to Book Ratio 0.00
Return on Assets (%) 5.58
Return on Capital (%) 6.35
Particulars MAR 2025 (Values in Cr)
Net Income 70.57
Cash from Operations -36.75
Cash from Investing -429.48
Cash from Financing 573.13
Net change in Cash 97.73
Free Cash Flow 120.77
Particulars MAR 2024 (Values in Cr)
Net Income 24.94
Cash from Operations -23.22
Cash from Investing -54.23
Cash from Financing 86.98
Net change in Cash 7.05
Free Cash Flow 28.61
Particulars MAR 2023 (Values in Cr)
Net Income 12.43
Cash from Operations 0.37
Cash from Investing -48.28
Cash from Financing 46.25
Net change in Cash -3.11
Free Cash Flow 47.65
Particulars MAR 2022 (Values in Cr)
Net Income 1.14
Cash from Operations -10.30
Cash from Investing -24.44
Cash from Financing 36.46
Net change in Cash 1.57
Free Cash Flow 0.37
Particulars MAR 2025 (Values in Cr)
Net Income 5.11
Cash from Operations -18.95
Cash from Investing -162.94
Cash from Financing 532.62
Net change in Cash 349.28
Free Cash Flow 30.16
Particulars MAR 2024 (Values in Cr)
Net Income 2.03
Cash from Operations -18.07
Cash from Investing -57.07
Cash from Financing 86.68
Net change in Cash 10.35
Free Cash Flow 1.19
Particulars MAR 2023 (Values in Cr)
Net Income 1.94
Cash from Operations -39.80
Cash from Investing -5.22
Cash from Financing 47.07
Net change in Cash -1.56
Free Cash Flow -31.42
Particulars MAR 2022 (Values in Cr)
Net Income 0.83
Cash from Operations -23.91
Cash from Investing -10.05
Cash from Financing 33.87
Net change in Cash -0.23
Free Cash Flow -23.43
Particulars MAR 2021 (Values in Cr)
Net Income 0.40
Cash from Operations -2.85
Cash from Investing -4.37
Cash from Financing 8.49
Net change in Cash 1.25
Free Cash Flow -0.06
Company Name Price P/E P/B Market Cap 52 Week Low 52 Week High
AMBALAL SARABHAI ENT L 32.40 13.39 1.56 248.29 23.12 38.85
BLISS GVS PHARMA LTD. 438.10 35.56 3.89 4646.32 118.35 462.70
CIPLA LTD. 1388.80 29.47 3.25 112193.56 1165.55 1672.20
FERMENTA BIOTECH LTD. 338.80 14.94 2.45 997.12 256.40 399.00
Company Name Price P/E P/B Market Cap 52 Week Low 52 Week High
AMBALAL SARABHAI ENT L 32.40 22.66 4.17 248.29 23.12 38.85
AMRUTAJAN HEALTH LTD 557.75 25.00 4.35 1612.49 490.00 789.95
ASTRAZENECA PHARMA IND LT 8243.90 107.66 23.61 20609.75 7630.00 10653.05
BLISS GVS PHARMA LTD. 438.10 47.26 4.02 4646.32 118.35 462.70

SENORES PHARMACEUTICALS L shareholding pattern

Holding
40.93%
45.81%
3.63%
9.61%
1.9%
Name Shares Category
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)

News

Left Arrow
Right Arrow

SENORES PHARMACEUTICALS L Technicals Summary

  • EMA & SMA
  • Resistance and Support
  • Delivery and Volume
  • Beta
  • Price Change Analysis
1283.20 -0.52 redarrow
red-green-graph indicator
0 Bearish
16 Bullish
  • 5 Days 1164.80
  • 26 Days 1060.90
  • 10 Days 1123.00
  • 50 Days 992.70
  • 12 Days 1113.40
  • 100 Days 913.40
  • 20 Days 1082.00
  • 200 Days 824.10
1157.00 PIVOT
First Support 1119.10 First Resistance 1198.60 Second Support 1077.50 Second Resistance 1236.50 Third Support 1039.60 Third Resistance 1278.10
RSI 73.91 ADX 44.01 MACD 52.57 Williams % R -2.03 Commodity Channel Index (CCI) 236.79
Date 2026-06-12 Week 244858.00 Same Day 510844.00 Month 245356.00
1 Year 1.11 3 Year 1.28
Over 1 Month
38.27% down
Over 1 Year
136.19% down
Over 3 Months
75.14% down
Over 3 Years
0.00% down
Over 6 Months
64.10% down
Over 5 Years
0.00% down

SENORES PHARMACEUTICALS L Corporate Actions

Top Gainers

Top Losers

stock
Trade stocks with ease

Sign-in to trade with your demat account, or set up a new demat account for free

Board Of Directors

Left Arrow
Right Arrow

Similar stocks

Left Arrow
Right Arrow

Frequently Asked Questions

What is the Current Share Price of Senores Pharmaceuticals Ltd?

Answer Field

Senores Pharmaceuticals Ltd share price is for NSE ₹ 1,283.20 & for BSE ₹ 1,264.80 as on Jun 15 2026 03:30 PM.

What is the Market Cap of Senores Pharmaceuticals Ltd Share?

Answer Field

The market cap of Senores Pharmaceuticals Ltd for NSE ₹ 0.00 & for BSE ₹ 0.00 as on Jun 15 2026 03:30 PM.

What is the 52 Week High and Low of Senores Pharmaceuticals Ltd?

Answer Field

The 52 Week High and Low of Senores Pharmaceuticals Ltd for NSE is ₹ 1,311.00 and ₹ 513.00 and for BSE is ₹ 1,310.10 and ₹ 507.00.

What is 1 year return for Senores Pharmaceuticals Ltd?

Answer Field

The 1 year returns on the stock has been 136.19%.

What is the P/E Ratio of Senores Pharmaceuticals Ltd Share?

Answer Field

As on Jun 15 2026 03:30 PM the price-to-earnings (PE) ratio for Senores Pharmaceuticals Ltd share is 293.47.

What is the PB ratio of Senores Pharmaceuticals Ltd Share?

Answer Field

As on Jun 15 2026 03:30 PM, the price-to-book (PB) ratio for Senores Pharmaceuticals Ltd share is 162.83.

How to Buy Senores Pharmaceuticals Ltd Share?

Answer Field

You can trade in Senores Pharmaceuticals Ltd shares with Bajaj Broking by opening a demat account.

How to Buy Senores Pharmaceuticals Ltd Share on Bajaj Broking App?

Answer Field

To buy Senores Pharmaceuticals Ltd shares on the Bajaj Broking app, follow these steps:

• Login to the Bajaj Broking App

• Click on the Search Icon

• Search “Senores Pharmaceuticals Ltd”

• Click on the BUY icon

• Place a buy order specifying the desired quantity of shares.

• Click BUY again to complete the purchase

No results found

close-image

Get Free Demat Account*

+91
close-img

Authorise with OTP

Enter the 4-Digit OTP sent to
edit
OTP expires in 00:59
banner-icon

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|

Please Enter Mobile Number

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|